

Primary Sclerosing Cholangitis Market - 2025-2033

<https://marketpublishers.com/r/P9E58CC0817BEN.html>

Date: March 2026

Pages: 243

Price: US\$ 2,999.00 (Single User License)

ID: P9E58CC0817BEN

Abstracts

The Primary Sclerosing Cholangitis Market was valued at US\$ 385.67 million in 2025 and is anticipated to reach US\$ 987.26 million by 2033, at a CAGR of 0.1221 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Primary Sclerosing Cholangitis Market.

This report delivers a comprehensive overview of the Primary Sclerosing Cholangitis Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Primary Sclerosing Cholangitis Market. The Primary Sclerosing Cholangitis Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2025–2033.

Primary Sclerosing Cholangitis Market Scope:

By Treatment

Medication-based Therapies

Bile Duct Blockages

Liver Transplantation

By Disease Stage

Early-stage

Moderate-stage

Advanced-stage

By Patient Age

Child

Adult

By End-User

Hospitals

Specialty Clinics

Others

Key Players

Chemomab Therapeutics Ltd.

Mirum Pharmaceuticals, Inc.

Ipsen S.A.

GENFIT

Gilead Sciences, Inc.

Pliant Therapeutics, Inc.

Immunic, Inc.

Dr. Falk Pharma GmbH

SCOHIA PHARMA, Inc.

Sirnaomics Ltd.

Major Highlights

This report delivers a comprehensive overview of the Primary Sclerosing Cholangitis Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Primary Sclerosing Cholangitis Market. The Primary Sclerosing Cholangitis Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2025–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients

with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

- 3.1. Snippet by Treatment
- 3.2. Snippet by Disease Stage
- 3.3. Snippet by Patient Age
- 3.4. Snippet by End-User
- 3.5. Snippet by Region

4. DYNAMICS

- 4.1. Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. Rising prevalence of primary sclerosing cholangitis
 - 4.1.2. Restraints
 - 4.1.2.1. Side effects associated with primary sclerosing cholangitis
 - 4.1.3. Opportunity
 - 4.1.3.1. Technological advancements
 - 4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

- 5.1. Porter's 5 Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Unmet Needs
- 5.4. Patent Analysis
- 5.5. Regulatory Analysis
- 5.6. SWOT Analysis
- 5.7. Russia-Ukraine Analysis
- 5.8. Artificial Intelligence Impact

6. COVID-19 ANALYSIS

6.1. Analysis of COVID-19

6.1.1. Scenario Before COVID-19

6.1.2. Scenario During COVID-19

6.1.3. Scenario Post COVID-19

6.2. Pricing Dynamics Amid COVID-19

6.3. Demand-Supply Spectrum

6.4. Government Initiatives Related to the Market During the Pandemic

6.5. Manufacturers' Strategic Initiatives

6.6. Conclusion

7. BY TREATMENT

7.1. Introduction

7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment

7.1.2. Market Attractiveness Index, By Treatment

7.2. Medication-based Therapies*

7.2.1. Introduction

7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

7.2.3. Bile acid sequestrants

7.2.4. Antibiotics

7.2.5. Antihistamines

7.2.6. Opioid antagonists

7.2.7. Ursodeoxycholic acid (UDCA)

7.3. Bile Duct Blockages

7.3.1. Balloon dilation

7.3.2. Stent placement

7.4. Liver Transplantation

8. BY DISEASE STAGE

8.1. Introduction

8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Stage

8.1.2. Market Attractiveness Index, By Disease Stage

8.2. Early-stage*

8.2.1. Introduction

8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

8.3. Moderate-stage

8.4. Advanced-stage

9. BY PATIENT AGE

9.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Age

9.2. Market Attractiveness Index, By Patient Age

9.3. Child*

9.3.1. Introduction

9.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

9.4. Adult

10. BY END-USER

10.1. Introduction

10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10.1.2. Market Attractiveness Index, By End-User

10.2. Hospitals*

10.2.1. Introduction

10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

10.3. Specialty Clinics

10.4. Others

11. BY REGION

11.1. Introduction

11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

11.1.2. Market Attractiveness Index, By Region

11.2. North America

11.2.1. Introduction

11.2.2. Key Region-Specific Dynamics

11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment

11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Stage

11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Age

11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

11.2.7.1. U.S.

11.2.7.2. Canada

11.2.7.3. Mexico

11.3. Europe

- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Stage
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Age
- 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 11.3.7.1. Germany
 - 11.3.7.2. U.K.
 - 11.3.7.3. France
 - 11.3.7.4. Italy
 - 11.3.7.5. Spain
 - 11.3.7.6. Rest of Europe
- 11.4. South America
 - 11.4.1. Introduction
 - 11.4.2. Key Region-Specific Dynamics
 - 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
 - 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Stage
 - 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Age
 - 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
 - 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 11.4.7.1. Brazil
 - 11.4.7.2. Argentina
 - 11.4.7.3. Rest of South America
- 11.5. Asia-Pacific
 - 11.5.1. Introduction
 - 11.5.2. Key Region-Specific Dynamics
 - 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
 - 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Stage
 - 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Age
 - 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
 - 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 11.5.7.1. China
 - 11.5.7.2. India
 - 11.5.7.3. Japan
 - 11.5.7.4. Australia
 - 11.5.7.5. Rest of Asia-Pacific
- 11.6. Middle East and Africa
 - 11.6.1. Introduction

11.6.2. Key Region-Specific Dynamics

11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment

11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Stage

11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Age

11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. COMPETITIVE LANDSCAPE

12.1. Competitive Scenario

12.2. Product Benchmarking

12.3. Company Share Analysis

12.4. Key Developments and Strategies

13. COMPANY PROFILES

13.1. Chemomab Therapeutics Ltd.*

13.1.1. Company Overview

13.1.2. Product Portfolio and Description

13.1.3. Financial Overview

13.1.4. Key Developments

13.2. Mirum Pharmaceuticals, Inc.

13.3. Ipsen S.A.

13.4. GENFIT

13.5. Gilead Sciences, Inc.

13.6. Pliant Therapeutics, Inc.

13.7. Immunic, Inc.

13.8. Dr. Falk Pharma GmbH

13.9. SCOHIA PHARMA, Inc.

13.10. Sirnaomics Ltd. (LIST NOT EXHAUSTIVE)

14. APPENDIX

14.1. About Us and Services

14.2. Contact Us

I would like to order

Product name: Primary Sclerosing Cholangitis Market - 2025-2033

Product link: <https://marketpublishers.com/r/P9E58CC0817BEN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P9E58CC0817BEN.html>